Revenue declined 27.6% year-over-year in Q2 2026, resulting in a net loss of $3.1 million as the company faced ongoing declines in its coach network and continued industry headwinds from GLP-1 medications. The company rebranded to Trilivy, launched new products, and maintained strong liquidity with $169.8 million in cash and investments.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.